NCT07187713View on ClinicalTrials.gov

ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases

PHASE4RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

September 20, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2026

Conditions
Hypertensive NephropathyAuto Immune DisordersChronic Kidney DiseaseChronc Kidney Disease Stage 5Chronic Kidney Disease (Stage 3-4)Chronic Kidney Disease (Stages 4 and 5)MicroalbuminuriaDiabetic Nephropathies
Interventions
DRUG

ACE Reno

1 ml sublingual 4 times daily for 12 weeks

Trial Locations (1)

12311

RECRUITING

British Centre For Regenerative medicine BCRMED Global, Giza

All Listed Sponsors
lead

Ace Cells Lab Limited

INDUSTRY